Expanding existing COVID-19 vaccine research collaboration which began in July 2020.

扩大2020年7月开始的COVID-19疫苗研究合作。

Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines)

Medytox和Dyadic将共同开发C1激活型COVID-19疫苗和/或增强剂，使人们对两种或两种以上当前和未来的COVID-19变种(如四价或四价COVID-19疫苗)免疫。

Exclusive license for Republic of Korea and multiple Southeast Asian countries, if successful

独家授权韩国和多个东南亚国家，如果成功

Manufacturing protocols to produce vaccines from C1 have been successfully transferred and reproduced at Medytox

从C1生产疫苗的生产方案已经在Medytox成功转移和复制

JUPITER, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics at flexible commercial scales, today announced that the Company is expanding its partnership with South Korea’s Medytox, Inc. (“Medytox”), a global biopharmaceutical company with sales in approximately 60 countries. Dyadic and Medytox will co-develop C1 manufactured COVID-19 vaccines and/or boosters, which will, if successful, be used to immunize people against two or more of the current and future COVID-19 variants. This project can provide dedicated local supply, to help combat COVID-19, in this region of the world.

木星,佛罗里达州。2021年3月22日(全球新闻通)- Dyadic International, Inc(“Dyadic”，“我们”，“我们的”，或“公司”)(纳斯达克:DYAI),全球生物科技公司专注于进一步改善,应用和部署其专有C1-cell蛋白质生产平台加快发展,降低生产成本和提高性能的生物疫苗和疗法在灵活的商业规模,今天宣布,该公司正在扩大其与韩国Medytox合作,Inc .(“Medytox”),全球生物制药公司销售大约60个国家。Dyadic和Medytox将共同开发C1生产的COVID-19疫苗和/或增强剂，如果成功，将用于对两种或两种以上当前和未来COVID-19变种进行免疫接种。该项目可以提供专门的当地供应，以帮助该地区抗击COVID-19。

Dr. Gi-Hyeok Yang, Sr, Executive Vice President and Head of Research and Development at Medytox stated, “We are very excited to extend our collaboration with Dyadic and their C1 technology platform to partner in the co-development of C1 manufactured COVID-19 vaccines.” Dr. Yang continued, “We have been working closely with Dyadic since July 2020, when we obtained access to their C1 expression platform and experienced the remarkable versatility and high productivity of the C1 platform. Based on our experience and comparing the C1 technology platform against several other expression platforms such as CHO and insect cells, we believe that the fungi-derived C1 expression system is the most realistic technology to develop and manufacture multi-valent (i.e., tri-valent, and tetra-valent) vaccines, rapidly and affordably, against COVID-19 mutant viruses without the need for a large-scale bioreactor facility. Medytox has confidence that the C1 technology platform can play a critical role in helping combat COVID-19, which may continue to persist as a seasonal influenza and necessitate COVID-19 variant vaccine shots every year. We look forward to gaining additional experience with the C1 technology as it has potential for use in developing and producing a growing number of vaccines, drugs, and other biological products in addition to COVID-19. As a biopharmaceutical company, with multiple successful commercial products, we look forward to leveraging our proven world-class research and development and commercialization capabilities to expeditiously bring potential new C1 manufactured COVID-19 variant vaccines to market, to combat this deadly infectious disease.”

Medytox执行副总裁兼研发主管Gi-Hyeok Yang博士表示:“我们非常高兴与Dyadic及其C1技术平台展开合作，共同开发C1生产的COVID-19疫苗。杨博士继续说道:“我们从2020年7月开始就与Dyadic密切合作，当时我们获得了他们的C1表达平台，并体验了其卓越的多功能性和高生产率。”基于我们的经验和比较C1技术平台与其他几个平台如秋和昆虫细胞表达,我们相信fungi-derived C1表达系统是最现实的技术开发和制造多才多艺的(例如,tri-valent,和tetra-valent)疫苗,迅速和经济化,COVID-19突变病毒不需要大规模的生物反应器设备。Medytox相信C1技术平台可以在帮助抗击COVID-19方面发挥关键作用，COVID-19可能继续作为季节性流感存在，需要每年接种COVID-19变种疫苗。我们期待在C1技术方面获得更多经验，因为除COVID-19外，C1技术还有潜力用于开发和生产越来越多的疫苗、药物和其他生物产品。作为一家生物制药公司，我们拥有多个成功的商业产品，我们期待利用我们久经考验的世界级研发和商业化能力，迅速将潜在的新C1制造的COVID-19变种疫苗推向市场，以抗击这种致命的传染病。”

Mark Emalfarb, Dyadic’s Founder and Chief Executive Officer commented, “If global efforts to eradicate the current pandemic are to be successful, there needs to be more efficient, affordable, and flexible ways to develop and manufacture vaccines globally, that can stop the spread of COVID-19. At Dyadic, we listened to early warnings from the scientific community and, as early as 2015, we joined with European human and animal health experts in the Zoonosis Anticipation Preparedness Initiative (ZAPI). In 2018, we expanded this effort with the Israel Institute for Biological Research (IIBR), to further develop our C1 gene expression platform for use in facilitating a fast, coordinated, and practical response to emerging infectious diseases.” Mr. Emalfarb continued, “If we are to achieve a better future, we must reduce or eliminate the risk of future pandemics, by acting now to invest in crucial research and development to optimize vaccination and drug strategies and technologies. A growing number of global scientists, industry and government agencies believe the C1 platform is positioning Dyadic as the partner of choice for high volume, low-cost, next generation vaccine and drug manufacturing, including COVID-19, influenza and other vaccines.”

Dyadic创始人兼首席执行官Mark Emalfarb表示:“如果全球根除当前大流行的努力要取得成功，就需要有更有效、负担得起和灵活的方式在全球开发和生产疫苗，从而阻止COVID-19的蔓延。在Dyadic，我们听取了科学界的早期预警，并且早在2015年，我们就与欧洲人类和动物卫生专家一起参与了人畜共患病预防倡议(ZAPI)。2018年，我们扩大了与以色列生物研究所(IIBR)的努力，进一步开发我们的C1基因表达平台，以促进快速、协调和实际应对新出现的传染病。埃马尔法布先生继续说:“如果我们要实现一个更美好的未来，我们必须减少或消除未来大流行病的风险，现在就行动起来，投资于关键的研发，以优化疫苗和药物战略和技术。”越来越多的全球科学家、行业和政府机构认为，C1平台正将Dyadic定位为大批量、低成本、下一代疫苗和药物生产的首选合作伙伴，包括COVID-19、流感和其他疫苗。”